

all 50 in the YK Delta, bringing the vaccine to pretty much anyone who wants it. In some villages, they have been able to vaccinate as much as half the population. As a result, the numbers of COVID infections and deaths are plummeting in this region, and hope is spreading.

This great team, Drs. Hodges and Bates, as well as all in the community and all working at YKHC, have made a huge difference, and this team has created a special bond that nobody will forget.

Dr. Bates, a relative newcomer to Alaska, says that the experience has made her fall in love with the YK Delta region even more. She bought a home. She intends on staying. She describes the beauty of the region, something that she appreciates even more now, as “Our sky is huge. . . . We have a front-row seat to the entire universe.”

These two doctors also have a front-row seat in providing a front-row seat to hope during this pandemic.

So I want to thank both of them again, Dr. Hodges and Dr. Bates, and all those across Alaska who are helping distribute the vaccine.

As I mentioned, right now, Alaska is the No. 1 State in the country per capita in terms of vaccine distribution and the No. 1 State per capita in terms of testing and has one of the lowest death rates. This is really amazing, really, when you see how big and widespread and harsh the weather conditions can be in the great State of Alaska.

Our fellow Alaskans are tough, resilient, and innovative, and Dr. Hodges and Dr. Bates are a huge and essential part of this effort. That is why I want to congratulate them and thank them again for being our Alaskans of the Week.

I yield the floor.

The PRESIDING OFFICER. The assistant majority leader.

ADVANCING EDUCATION ON BIOSIMILARS ACT OF 2021

Mr. DURBIN. Madam President, I ask unanimous consent that the Committee on Health, Education, Labor, and Pensions be discharged from further consideration of S. 164 and the Senate proceed to its immediate consideration.

The PRESIDING OFFICER. The clerk will report the bill by title.

The legislative clerk read as follows:

A bill (S. 164) to educate health care providers and the public on biosimilar biological products, and for other purposes.

There being no objection, the committee was discharged and the Senate proceeded to consider the bill.

Mr. DURBIN. I ask unanimous consent that the bill be considered read a third time and passed and the motion to reconsider be considered made and laid upon the table.

The PRESIDING OFFICER. Without objection, it is so ordered.

The bill (S. 164) was ordered to be engrossed for a third reading, was read the third time, and passed, as follows:

S. 164

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Advancing Education on Biosimilars Act of 2021”.

SEC. 2. EDUCATION ON BIOLOGICAL PRODUCTS.

Subpart 1 of part F of title III of the Public Health Service Act (42 U.S.C. 262 et seq.) is amended by adding at the end the following:

“SEC. 352A. EDUCATION ON BIOLOGICAL PRODUCTS.

“(a) INTERNET WEBSITE.—

“(1) IN GENERAL.—The Secretary may maintain and operate an internet website to provide educational materials for health care providers, patients, and caregivers, regarding the meaning of the terms, and the standards for review and licensing of, biological products, including biosimilar biological products and interchangeable biosimilar biological products.

“(2) CONTENT.—Educational materials provided under paragraph (1) may include—

“(A) explanations of key statutory and regulatory terms, including ‘biosimilar’ and ‘interchangeable’, and clarification regarding the use of interchangeable biosimilar biological products;

“(B) information related to development programs for biological products, including biosimilar biological products and interchangeable biosimilar biological products and relevant clinical considerations for prescribers, which may include, as appropriate and applicable, information related to the comparability of such biological products;

“(C) an explanation of the process for reporting adverse events for biological products, including biosimilar biological products and interchangeable biosimilar biological products; and

“(D) an explanation of the relationship between biosimilar biological products and interchangeable biosimilar biological products licensed under section 351(k) and reference products (as defined in section 351(i)), including the standards for review and licensing of each such type of biological product.

“(3) FORMAT.—The educational materials provided under paragraph (1) may be—

“(A) in formats such as webinars, continuing education modules, videos, fact sheets, infographics, stakeholder toolkits, or other formats as appropriate and applicable; and

“(B) tailored for the unique needs of health care providers, patients, caregivers, and other audiences, as the Secretary determines appropriate.

“(4) OTHER INFORMATION.—In addition to the information described in paragraph (2), the Secretary shall continue to publish—

“(A) the action package of each biological product licensed under subsection (a) or (k) of section 351; or

“(B) the summary review of each biological product licensed under subsection (a) or (k) of section 351.

“(5) CONFIDENTIAL AND TRADE SECRET INFORMATION.—This subsection does not authorize the disclosure of any trade secret, confidential commercial or financial information, or other matter described in section 552(b) of title 5.

“(b) CONTINUING EDUCATION.—The Secretary shall advance education and awareness among health care providers regarding biological products, including biosimilar biological products and interchangeable biosimilar biological products, as appropriate, including by developing or improving continuing education programs that advance the education of such providers on the prescribing of, and relevant clinical consider-

ations with respect to, biological products, including biosimilar biological products and interchangeable biosimilar biological products.”.

FOOD ALLERGY SAFETY, TREATMENT, EDUCATION, AND RESEARCH ACT OF 2021

Mr. DURBIN. Madam President, I ask unanimous consent that the Senate proceed to the immediate consideration of S. 578, which was introduced earlier today.

The PRESIDING OFFICER. The clerk will report the bill by title.

The legislative clerk read as follows:

A bill (S. 578) to improve the health and safety of Americans living with food allergies and related disorders, including potentially life-threatening anaphylaxis, food protein-induced enterocolitis syndrome, and eosinophilic gastrointestinal diseases, and for other purposes.

There being no objection, the Senate proceeded to consider the bill.

Mr. DURBIN. I further ask that the bill be read a third time and passed and the motion to reconsider be considered made and laid upon the table with no intervening action or debate.

The PRESIDING OFFICER. Without objection, it is so ordered.

The bill (S. 578) was ordered to be engrossed for a third reading, was read the third time, and passed, as follows:

S. 578

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Food Allergy Safety, Treatment, Education, and Research Act of 2021” or the “FASTER Act of 2021”.

SEC. 2. FOOD ALLERGY SAFETY.

(a) IN GENERAL.—Section 201(qq)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(qq)(1)) is amended by striking “and soybeans” and inserting “soybeans, and sesame”.

(b) EFFECTIVE DATE.—The amendment made by subsection (a) shall apply to any food that is introduced or delivered for introduction into interstate commerce on or after January 1, 2023.

SEC. 3. REPORT TO CONGRESS.

(a) REPORT.—Not later than 18 months after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report that includes—

(1) descriptions of ongoing Federal activities related to—

(A) the surveillance and collection of data on the prevalence of food allergies and severity of allergic reactions for specific food or food ingredients, including the identification of any gaps in such activities;

(B) the development of effective food allergy diagnostics;

(C) the prevention of the onset of food allergies;

(D) the reduction of risks related to living with food allergies; and

(E) the development of new therapeutics to prevent, treat, cure, and manage food allergies; and

(2) specific recommendations and strategies to expand, enhance, or improve activities described in paragraph (1), including—

(A) strategies to improve the accuracy of food allergy prevalence data by expanding and intensifying current collection methods, including support for research that includes the identification of biomarkers and tests to validate survey data and the investigation of the use of identified biomarkers and tests in national surveys;

(B) strategies to overcome gaps in surveillance and data collection activities related to food allergies and specific food allergens; and

(C) recommendations for the development and implementation of a regulatory process and framework that would allow for the timely, transparent, and evidence-based modification of the definition of "major food allergen" included in section 201(qq) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. 321(qq)), including with respect to—

(i) the scientific criteria for defining a food or food ingredient as a "major food allergen" pursuant to such process, including recommendations pertaining to evidence of the prevalence and severity of allergic reactions to a food or food ingredient that would be required in order to establish that such food or food ingredient is an allergen of public health concern appropriate for such process; and

(ii) opportunities for stakeholder engagement and comment, as appropriate, in considering any such modification to such definition.

(b) PUBLICATION.—The Secretary shall make the report under subsection (a) available on the internet website of the Department of Health and Human Services.

MAKING A TECHNICAL CORRECTION TO THE ALS DISABILITY INSURANCE ACCESS ACT OF 2019

Mr. DURBIN. Madam President, I ask unanimous consent that the Senate proceed to the immediate consideration of S. 579, which was introduced earlier today.

The PRESIDING OFFICER. The clerk will report the bill by title.

The legislative clerk read as follows:

A bill (S. 579) to make a technical correction to the ALS Disability Insurance Access Act of 2019.

There being no objection, the Senate proceeded to consider the bill.

Mr. DURBIN. I further ask that the bill be read a third time and passed and the motion to reconsider be considered made and laid upon the table with no intervening action or debate.

The PRESIDING OFFICER. Without objection, it is so ordered.

The bill (S. 579) was ordered to be engrossed for a third reading, was read the third time, and passed, as follows

S. 579

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. RETROACTIVE ACCESS TO SOCIAL SECURITY DISABILITY BENEFITS INDIVIDUALS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS).

(a) IN GENERAL.—Section 2(b) of the ALS Disability Insurance Access Act of 2019 (Public Law 116-250) is amended by striking "applications for disability insurance benefits filed after the date of enactment of this Act" and inserting "applications for disability insurance benefits approved after the date that is 5 months before the date of enactment of this Act".

(b) EFFECTIVE DATE.—The amendment made by this section shall take effect as if included in the enactment of the ALS Disability Insurance Access Act of 2019 (Public Law 116-250).

RESOLUTIONS SUBMITTED TODAY

Mr. DURBIN. Madam President, I ask unanimous consent that the Senate now proceed to the en bloc consideration of the following Senate resolutions, which were submitted earlier today: S. Res. 90, S. Res. 91, S. Res. 92, and S. Res. 93.

There being no objection, the Senate proceeded to consider the resolutions en bloc.

Mr. DURBIN. I ask unanimous consent that the resolutions be agreed to, the preambles be agreed to, and the motions to reconsider be considered made and laid upon the table, all en bloc.

The PRESIDING OFFICER. Without objection, it is so ordered.

The resolutions were agreed to.

The preambles were agreed to.

(The resolutions, with their preambles, are printed in today's RECORD under "Submitted Resolutions.")

NATIONAL TRIBAL COLLEGES AND UNIVERSITIES WEEK

Mr. DURBIN. Mr. President, I ask unanimous consent that the Senate proceed to the consideration of S. Res. 94, submitted earlier today.

The PRESIDING OFFICER. The clerk will report the resolution by title.

The legislative clerk read as follows:

A resolution (S. Res. 94) designating the week beginning February 28, 2021, as "National Tribal Colleges and Universities Week".

There being no objection, the Senate proceeded to consider the resolution.

Mr. DURBIN. I know of no further debate on the resolution.

The PRESIDING OFFICER. If there is no further debate, the question is on agreeing to the resolution.

The resolution (S. Res. 94) was agreed to.

Mr. DURBIN. I ask unanimous consent that the preamble be agreed to and the motions to reconsider be considered made and laid upon the table with no intervening action or debate.

The PRESIDING OFFICER. Without objection, it is so ordered.

The preamble was agreed to.

(The resolution, with its preamble, is printed in today's RECORD under "Submitted Resolutions.")

REMEMBERING BILL NIGHBERT

Mr. McCONNELL. Madam President, earlier this year, my home State of Kentucky said goodbye to Bill Nighbert, a longtime public servant and a kindhearted friend. Both as a local mayor and a statewide official, Bill was instrumental to the achievements of communities across our Com-

monwealth. Today, I would like to recognize his lifetime of contributions to Kentucky.

As the Gateway to the Cumberland, the city of Williamsburg holds a special significance not just in Southeastern Kentucky but for the entire Commonwealth. Bill worked several jobs for the city he loved before being elected mayor in 1993. For the next decade, the people of Williamsburg put their trust in him. In return, Bill worked around the clock to deliver for his community. Even in the city's top job, Bill could still be found helping plow snow, deliver goods, or any other job that needed doing. A beloved local splash park is just one tangible example of Bill's leadership and vision for his city.

As a successful mayor, Bill's reputation grew across the Commonwealth. He was elected president of the Kentucky League of Cities in 2002, using his talents to improve communities throughout the Bluegrass. Bill left city hall when Governor Ernie Fletcher tapped him to be deputy commissioner of the Department of Local Government and later the secretary of the Transportation Cabinet. Even as Bill served the entire Commonwealth in Frankfort, he still took care of Whitley County. For instance, he was a driving force in the construction of a new interchange over I-75 near Williamsburg.

Apart from his professional work, Bill was legendary for his ability to make a friend in any situation. I guess you don't become the president of the Optimists Club without a sunny disposition. He was a role model and a little league coach, lending whatever free time he could find to a variety of local organizations.

Of course, Bill's greatest achievement was the love he shared with his wife of 34 years, Susan, as well as his children and their spouses, Brad and Monica, Renee and Chris, and Benton. Anyone who was lucky enough to know Bill could see the immense pride he had in his children and grandchildren. He said they were the reasons he dedicated so much of his life to public service. On behalf of the Senate, I send sincere condolences to Bill's friends and loved ones. We are grateful they shared him with us for so many years. Kentucky was made better as a result.

NOTICE OF A TIE VOTE UNDER S. RES. 27

Mr. WYDEN. Madam President, I ask unanimous consent to print the following letter in the CONGRESSIONAL RECORD.

There being no objection, the material was ordered to be printed in the RECORD, as follows:

To the Secretary of the Senate:

PN78-2, the nomination of Xavier Becerra, of California, to be Secretary of Health and Human Services having been referred to the Committee on Finance, the Committee, with a quorum present, has voted on the nomination as follows—